A recent investigation reveals that the FDA may have been lenient when approving the newer generation anticoagulant.
This investigative study was conducted by the nonpartisan Project on Government Oversight (POGO), which indicated that the FDA had approved the drug based on poorly designed clinical trials that grossly overlooked patient safety concerns over Pradaxa side effects.
Additionally, Boehringer Ingelheim allegedly ignored its own concerns regarding the lack of precautionary warnings on Pradaxa’s warning label.
Pradaxa is a new-generation anticoagulant that was approved by the FDA in 2010, to be an alternative to Warfarin. Its approval was a landmark in American pharmaceutical history as it was the first anticoagulant to break through into that specific drug market for decades.
It soon outpaced Warfarin in popularity, due to its advertisements stating that it was prescribed in a single dose and worked more efficiently than the older drug.
However, just as quickly as it was released, patients complained of suffering irreversible bleeding events, which required emergency intervention.
This eventually drew so much negative attention that a consolidated litigation movement was established against Boehringer Ingelheim, Pradaxa’s manufacturer.
Furthermore, recent studies have been suggesting that Boehringer Ingelheim and the FDA were too lax in the drug’s release, suggesting that the drug’s risk has always been much higher than its benefits.
Overview of Pradaxa Bleeding Complications
The POGO report begins with the story of a retired social worker named Sidney Denham, who had experienced severe gastrointestinal bleeding from his urinary tract after being prescribed Pradaxa; he had recently undergone prostate surgery.
These internal bleeding injuries had eventually led to his death, in which the doctor reported the cause of death as “uncontrollable hemorrhage from Pradaxa” as a contributing cause.
Dr. Bryan Cotton then started discussing his own experiences in witnessing these Pradaxa side effects in his own patients at the University of Texas Medical Center, with 25 patients needing emergency room visits.
He published his observations in the New England Journal of Medicine in 2011, stating that it is frustrating to inform unsuspecting families that Pradaxa has no bleeding remedy.
In conducting the investigation, eight POGO employees had sorted through thousands of files from court cases and open records requests, for over two years; this was to trace the time line between Pradaxa’s approval and the product liability claims.
The research showed that researchers had removed Pradaxa patients who exhibited early side effects, which significantly effected the results.
Additionally, an FDA review had found that the way the trial was conducted was designed to show that Pradaxa appeared to perform better than Warfarin. Neither Warfarin or Pradaxa patients hadtheir blood tested for thickness, which further skewed the results against Warfarin.
These and other troubling finds made in the POGO report prompted the nonprofit to declare the clinical trial process for Pradaxa “a sausage factory”. These findings were presented in a recent report, claiming that there were significant flaws in almost every stage of the pre-approval process of Pradaxa.
The watchdog group criticized the FDA for allegedly overlooking obvious risks and supporting false advertising claims for Pradaxa. POGO’s report could not have come at a worse time for the FDA, as Congress is currently considering to implement the 21st Century Cures Act; this would quicken the FDA’s approval process and increase the amount of work for the affect.
Officials from Boehringer Ingelheim had discussed their clinical trials with POGO in 2013, calling the article too biased and misleading towards patients and physicians.
Meanwhile, patients and doctors continue to suffer the ambiguity in the warning label and the injury reports, with many reporting severe internal bleeding injuries. A number of them have filed product liability lawsuits against Boehringer Ingelheim, for failing to warn them against Pradaxa bleeding risks.
In general, Pradaxa lawsuits are filed individually by each plaintiff and are not class actions.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Pradaxa attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Pradaxa class action lawsuit is best for you. Hurry — statutes of limitations may apply.
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2015 Top Class Actions® LLC
Various Trademarks held by their respective owners
Get Help – It’s Free
Join a Free Pradaxa Class Action Lawsuit Investigation
If you, or a loved one, experienced Pradaxa side effects, you may have a legal claim. Submit your information now for a free case evaluation.
An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.
- First Name*
- Last Name*
- Street Address*
- Apt. #
- City*
- State*
AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareDistrict of ColumbiaFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingArmed Forces AmericasArmed Forces EuropeArmed Forces Pacific
- Zip Code*
- Phone*
- Email*
- Which blood thinner did you or a loved one take at the time of the injury or injuries?*
- Pradaxa
- Xarelto
- Unknown
- Other
- Please check the injuries suffered:*
-
Death
-
Gastrointestinal Bleeding
-
Other Internal Bleeding
-
Cerebral Hemorrhaging
-
Unsure
-
None
-
- ¿Necesita un orador español?
- Yes
- No
- Please enter any additional details you would like the staff reviewing your submission to know.*
- I understand and agree that submitting this form does not create an attorney-client relationship and that the information I submit is not confidential or privileged and may be shared.*
-
Yes
-
-
if(typeof gf_global == ‘undefined’) var gf_global = {“gf_currency_config”:{“name”:”U.S. Dollar”,”symbol_left”:”$”,”symbol_right”:””,”symbol_padding”:””,”thousand_separator”:”,”,”decimal_separator”:”.”,”decimals”:2},”base_url”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms”,”number_formats”:[],”spinnerUrl”:”http:\/\/topclassactions.com\/wp-content\/plugins\/gravityforms\/images\/spinner.gif”};jQuery(document).bind(‘gform_post_render’, function(event, formId, currentPage){if(formId == 24) {gformInitChosenFields(‘#input_24_5′,’No results matched’);if(!/(android)/i.test(navigator.userAgent)){jQuery(‘#input_24_7’).mask(‘(999) 999-9999’).bind(‘keypress’, function(e){if(e.which == 13){jQuery(this).blur();} } );}} } );jQuery(document).bind(‘gform_post_conditional_logic’, function(event, formId, fields, isInit){gformInitChosenFields(‘#input_24_5′,’No results matched’);} ); jQuery(document).ready(function(){jQuery(document).trigger(‘gform_post_render’, [24, 1]) } );
The post Watchdog Study Says FDA’s Release of Pradaxa Was Faulty appeared first on Top Class Actions.
No comments:
Post a Comment